Phase I study for assessment of safety of gene therapy with GX-12 in combination with HAART for the HIV-1 infected patients
Phase of Trial: Phase I
Latest Information Update: 27 Feb 2017
At a glance
- Drugs Antiretrovirals; GX 12
- Indications HIV-1 infections
- Focus Adverse reactions
- Sponsors Genexine
- 07 Jun 2017 Biomarkers information updated
- 22 Jun 2013 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently' (last verified May 2008).
- 11 May 2008 The expected completion date for this trial is now 1 Dec 2009 according to ClinicalTrials.gov.